Infinity Pharmaceuticals, Inc. recently provided an update on the commercial overview and clinical development program for duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, two proteins with predominantly non-overlapping ... Read more